Hiroyuki Fujinaga

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Kausik K Ray, Helen M Colhoun, Michael Szarek et al. · The Lancet Diabetes & Endocrinology · 2019 · 328 citations · Full text

Medicine, Cardiology, Internal Medicine +15

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

Gregory G. Schwartz, Vera A. Bittner, Patricio López‐Jaramillo et al. · Journal of the American College of Cardiology · 2021 · 141 citations · Full text

Medicine, Cardiology, Pharmacology +17

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

Emil Hagström, Philippe Gabríel Steg, Michael Szarek et al. · Circulation · 2022 · 122 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Features and Outcomes of Histologically Proven Myocarditis With Fulminant Presentation

Koshiro Kanaoka, Kenji Onoue, Satoshi Terasaki et al. · Circulation · 2022 · 59 citations · Full text

Medicine, Cardiology, Internal Medicine +13

Right and Left Ventricular Wall Motion Velocities as Diagnostic Indicators of Constrictive Pericarditis

Takashi Oki, Tomotsugu Tabata, Hirotsugu Yamada et al. · The American Journal of Cardiology · 1998 · 43 citations

Medicine, Cardiology, Clinical Cardiology +12